BG
CLDX icon

Bellevue Group’s Celldex Therapeutics CLDX Stock Holding History

Bellevue Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.1M Sell
1,200,000
-2,417,669
-67% -$65.9M 0.91% 34
2025
Q4 		$98.3M Buy
3,617,669
+60,000
+2% +$1.58M 1.86% 17
2025
Q3 		$92M Buy
3,557,669
+250,100
+8% +$5.8M 1.91% 17
2025
Q2 		$67.3M Buy
3,307,569
+235,954
+8% +$4.59M 1.48% 20
2025
Q1 		$55.7M Hold
3,071,615
– – 1.25% 20
2024
Q4 		$77.6M Hold
3,071,615
– – 1.49% 20
2024
Q3 		$104M Buy
3,071,615
+100,000
+3% +$3.81M 1.69% 16
2024
Q2 		$110M Buy
2,971,615
+175,000
+6% +$6.6M 1.79% 17
2024
Q1 		$117M Buy
2,796,615
+380,319
+16% +$15.6M 1.79% 16
2023
Q4 		$95.8M Buy
2,416,296
+516,296
+27% +$15.2M 1.47% 17
2023
Q3 		$52.3M Buy
1,900,000
+100,000
+6% +$3.13M 0.84% 29
2023
Q2 		$61.1M Hold
1,800,000
– – 0.87% 33
2023
Q1 		$64.8M Hold
1,800,000
– – 0.94% 37
2022
Q4 		$80.2M Hold
1,800,000
– – 1.06% 27
2022
Q3 		$50.6M Buy
1,800,000
+875,000
+95% +$26.8M 0.73% 44
2022
Q2 		$24.9M Buy
+925,000
New +$26.9M 0.35% 77
2017
Q4 		– Sell
-10,667
Closed -$458K – 135
2017
Q3 		$458K Hold
10,667
– – 0.05% 126
2017
Q2 		$395K Hold
10,667
– – 0.05% 128
2017
Q1 		$578K Hold
10,667
– – 0.08% 119
2016
Q4 		$566K Hold
10,667
– – 0.12% 106
2016
Q3 		$646K Hold
10,667
– – 0.12% 112
2016
Q2 		$702K Hold
10,667
– – 0.13% 105
2016
Q1 		$605K Buy
+10,667
New +$1.2M 0.11% 108

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Bellevue Group's CLDX Position: Q1 2026 in Review

Bellevue Group reduced its Celldex Therapeutics (CLDX) stake by 67% in Q1 2026, selling an estimated $65.9M and leaving 1,200,000 shares worth $38.1M. The position accounts for 0.91% of the portfolio, ranked #34.

Bellevue Group first reported a position in CLDX in Q1 2016 and has held it in 23 quarters since. The position peaked at $117M in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Bellevue Group held 1,200,000 shares of Celldex Therapeutics worth $38.1M as of Q1 2026.
  • Bellevue Group sold 2,417,669 Celldex Therapeutics shares in Q1 2026, an estimated $65.9M.
  • Celldex Therapeutics made up 0.91% of Bellevue Group's portfolio in Q1 2026, its #34 holding.
  • Bellevue Group first reported a position in Celldex Therapeutics in Q1 2016 and has held it in 23 quarters since.
  • Bellevue Group's Celldex Therapeutics position peaked at $117M in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.